Panelists Adam M. Brufsky, MD, PhD; José Baselga, MD, PhD; Kimberly L. Blackwell, MD; Denise A. Yardley, MD; Debu Tripathy, MD; and Carlos L. Arteaga, MD, discuss the positive results of the large phase III APHINITY trial looking at adjuvant chemotherapy and trastuzumab plus pertuzumab and comment on the implications for clinical practice in breast cancer.
